ESMO Recommendations on clinical reporting of genomics test results for solid cancers

(5:58)

ESMO Recommendations for Use of Tumour Multigene NGS in Metastatic Cancers

(5:49)

The ESMO Guidelines On Salivary Gland Cancers With Prof. Carla van Herpen | SGC UK

(15:29)

ESMO 2024 Oncologists Burnout Insights

(2:51)

COVID-19 and cancer: the ESMO recommendations for clinical practice

(2:30)

MAP 2024: shaping the future of precision oncology

(1:45)

Updates to the ESMO clinical practice guidelines for CLL

(2:19)

ASCO 2024 and ESMO GI 2024 Updates Webinar | Feat. Dr. Samuel Klempner

(1:3:54)

ESMO OncologyPRO - Intro by Dr. E. SMYTH

(1:46)

\

(1:29:29)

ESICM Guidelines for ARDS 2023

(19:59)

ESMO 2024: Highlights and analysis

(24:35)

BEST OF ELCC ESMO BREAST 2024

(2:8:12)

ESICM Guidelines 2023 on ARDS: Definition

(2:39:57)

2023 What Changes Monday Morning? | ESMO Breast Cancer Webinar

(1:35:10)

ESMO 2023 Lung Cancer Highlights – Keynote 671 | ALINA | TropionLung01 | Oncology Brothers

(18:24)

Expanding horizons in the treatment of endometrial cancer: ESGO 2023 guide clinical practice?

(1:25)

Expert report on immune checkpoint inhibitors for dMMR Colorectal Cancer

(5:30)

ESCAT - How to classify genomic alterations according level of actionability

(4:22)

ESMO Vision stories of Specialised Education: Elizabeth Smyth, ESMO Guidelines author

(1:48)

Key updates and changes to the ESMO clinical practice guidelines for CLL

(1:29)

Recommendations for the use of NGS in patients with metastatic cancer

(4:2)

ESMO Clinical Practice Guidelines: beyond EGFR and ALK

(2:47)

Next Generation Sequencing for Patients with Advanced Cancers | ESMO PMWG Recommendations 2024

(12:57)

#MAP2020: Tumour profiling and precision oncology - don’t fear the germline

(3:51)

Controversy Debate 4: Treatment algorithms in metastatic CRC - ESMO guidelines

(19:52)

2024 Metastatic Urothelial Carcinoma Guidelines: NCCN, EAU, ESMO

(26:18)

ESMO Vision stories of Specialised Education: Silke Gillessen, ESMO Guidelines Committee member

(2:4)